Cogent Biosciences Stock Forecast
NASDAQ: COGTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
COGT analyst consensus
Consensus (12 analysts)
strong_buy
Avg. price target
$55.82+85.57%
- Strong buy 2
- Buy 9
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 12 Wall Street analysts covering Cogent Biosciences (2026-10-09), 11 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $55.82, with a high estimate of $62.00 and a low estimate of $45.00. The average target implies upside of 85.6% from the current price of $30.08.
The spread between the highest and lowest targets is 37.8%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for COGT.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 17% |
| Buy | 9 | 75% |
| Hold | 1 | 8% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $45.00 | +49.60% |
| Average target | $55.82 | +85.57% |
| High target | $62.00 | +106.12% |